-
Feb 10, 2025 | 
insights.citeline.com | Bridget Silverman |Nancy Pham |Kosh Naran
Novel Agents Up For US FDA Approval In 2025CBER has at least 14 and CDER another 10 novel biologics among the more than 60 candidates with a user fee goal in 2025. The FDA's 2025 user fee calendar includes a wide range of product types. (Shutterstock)
-
Nov 25, 2024 | 
insights.citeline.com | Edwin Elmhirst |Kosh Naran
Scrip 100: By The NumbersDespite experiencing significant drops in pharmaceutical revenues in 2023, Pfizer and AbbVie maintained their top positions, ranking first and second respectively, in the latest Scrip 100.
-
Oct 21, 2024 | 
insights.citeline.com | Eleanor Malone |Kosh Naran
Titans Of Pharma: Pfizer’s Bourla Tops Big Pharma CEO Compensation LeagueBourla’s Total Package Exceeds $30mInfographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.
-
Oct 16, 2024 | 
insights.citeline.com | Marion Webb |Kosh Naran
AI In Health Care: Speakers At HLTH Europe Conference Discuss Promise And PitfallsAI is all the rage these days, so it comes as no surprise that the topic of AI technologies ranked high during the panel discussions at the HLTH Europe event, held from 17-20 June in Amsterdam.
-
Oct 15, 2024 | 
insights.citeline.com | Vibha Ravi |Kosh Naran
BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps? Lilly’s Mounjaro to Pfizer’s Paxlovid, the WuXi group has been part of pharma majors’ sourcing chain. How big is the hole clients are to fill when the proposed BIOSECURE Act comes into effect? Here’s a Scrip infographic using Evaluate Pharma data. The BIOSECURE Act - How Much Of A Game Changer For US Companies? • Source: Shutterstock
-
Oct 15, 2024 | 
insights.citeline.com | Eleanor Malone |Brianna Molnar |Kosh Naran
Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation AgainGorsky And Stoffels Go Out On A HighInfographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics. How much did the leaders of the top 20 pharma companies get paid last year? • Source: Shutterstock
-
Sep 23, 2024 | 
scrip.citeline.com | Vibha Ravi |Kosh Naran
Data
Executive Summary
Lilly’s Mounjaro to Pfizer’s Paxlovid, the WuXi group has been part of pharma majors’ sourcing chain. How big is the hole clients are to fill when the proposed BIOSECURE Act comes into effect? Here’s a Scrip infographic using Evaluate Pharma data.
-
Jul 22, 2024 | 
invivo.citeline.com | Eleanor Malone |Edwin Elmhirst |Kosh Naran
Analysis
Executive Summary
J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.
Existing Subscriber?
Sign in to continue reading.
New to In Vivo?
-
Jul 22, 2024 | 
invivo.citeline.com | Eleanor Malone |Edwin Elmhirst |Kosh Naran |Marion Webb
Acccess Token :
Refresh Token :
Entitlement Claim :
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Existing Subscriber?
-
Jul 22, 2024 | 
invivo.citeline.com | Eleanor Malone |Edwin Elmhirst |Kosh Naran |Jessica Merrill
Acccess Token :
Refresh Token :
Entitlement Claim :
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Existing Subscriber?
